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Squamous cell carcinoma (SCC) of the tongue is the most common cancer in the oral cavity and has a high mortality rate. A total of
90 mobile tongue SCC samples were analysed for Bryne’s malignancy scores, microvascular density, and thickness of the SCC
sections. In addition, the staining pattern of cyclooxygenase-2, avb6 integrin, the laminin-5 g2-chain, and matrix metalloproteinases
(MMPs) -2, -7, -8, -9, -20, and -28 were analysed. The expression of MMP-8 (collagenase-2) was positively associated with improved
survival of the patients and the tendency was particularly prominent in females. No sufficient evidence for a correlation with the
clinical outcome was found for any other immunohistological marker. To test the protective role of MMP-8 in tongue carcinogenesis,
MMP-8 knockout mice were used. MMP-8 deficient female mice developed tongue SCCs at a significantly higher incidence than wild-
type mice exposed to carcinogen 4-Nitroquinoline-N-oxide. Consistently, oestrogen-induced MMP-8 expression in cultured HSC-3
tongue carcinoma cells, and MMP-8 cleaved oestrogen receptor (ER) a and b. According to these data, we propose that, contrary to
the role of most proteases produced by human carcinomas, MMP-8 has a protective, probably oestrogen-related role in the growth
of mobile tongue SCCs.
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Squamous cell carcinoma (SCC) of the tongue is the most common
type of cancer in the oral cavity and its incidence has increased
over the past decades worldwide (Swango, 1996; Alho et al, 1999).
SCCs of the tongue behave aggressively and almost half of the
patients still die of the disease (Dickman et al, 1999). Efficient
intervention of tongue SCCs requires the identification of the most
aggressively behaving tumours. Over the past few years, a series of
studies have tried to define immunoreactive molecular markers
with ability to predict disease recurrence and prognosis of oral
SCC patients (Bettendorf et al, 2004; Brinkman and Wong, 2006).
In this work, we have addressed this question by analysing at both
clinical and molecular levels, a series of tongue cancer cases. This
population-based study covered all the patients in Northern
Finland with surgically treated SCC in the mobile tongue between
the years 1981–2001. Resection samples from 90 eligible mobile
tongue SCC patients (47 males, 43 females) were analysed using a
set of possible new and previously proposed immunohistochemical
prognostic markers including microvessel density (CD31 and
factor VIII), cyclooxygenase-2 (COX-2), the laminin-5 g2-chain,
integrin avb6 and matrix metalloproteinases (MMP-2, -7, -8, -9,
-20, and -28). The high expression levels of COX-2 are known to be
associated with poor disease-free survival in oral squamous cell
carcinoma (Pannone et al, 2007) and also laminin-5 g2-chain, a
basement membrane protein (Gasparoni et al, 2007), and avb6
integrin, a transmembrane adhesion protein (Hynes, 1992) are
known to be increased in invasive SCCs (Breuss et al, 1995; Jones
et al, 1997; Ramos et al, 1997). Angiogenesis is crucial for tumour
growth (Folkman et al, 1963) and metastasis (Folkman, 1990) but
the role of angiogenesis is still controversial in oral SCC (Gasparini
et al, 1993; Leedy et al, 1994; Hogmo et al, 1999; Macluskey et al,
2000) and thus deserves further investigation. MMPs cleave almost
all extracellular matrix proteins but differ in substrate specificity.
These enzymes can be divided into the collagenases (MMP-1,
-8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10
and -11), matrilysins (MMP-7 and -26), membrane-type MMPs
and other MMPs (Overall and Lopez-Otin, 2002). Previous studies
have shown inconsistent results with the expression of various
MMPs and the outcome of the patients with oral carcinomas.
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sHowever, in virtually all these previous studies, a heterogenous set
of tumours have been analysed and therefore the results may not
be comparable (Guttman et al, 2004; Ruokolainen et al, 2004).
Identification of any of these factors as a potential prognostic
marker would be useful for estimating the behaviour of the tumour
and the survival of the patient with SCC in the mobile tongue.
In this work, we provide evidence that collagenase-2 (MMP-8) is a
protective factor in mobile tongue SCC. Furthermore, and by using
mice deficient in this metalloproteinase and oral carcinoma cells
producing MMP-8, we examine putative molecular and cellular
mechanisms underlying the protective effect of this enzyme in
tongue cancer.
MATERIALS AND METHODS
Patients
All 90 patients treated surgically (with at least 5mm histological
margins) at the Oulu University hospital with diagnosed mobile
tongue SCC during the years 1981–2001 were included in this
study. This tertiary care centre provides primary treatment for all
cancer patients in the two northernmost provinces of Finland,
covering a population of B650000 inhabitants. The patients (47
males, 43 females) were 26–99 years of age at the diagnosis of SCC
(median 62 years). The following tumour-related factors were
collected from the hospital files: tumour grade according to the
classification (Pindborg et al 1987) and TNM stage of the tumour
(International Union Against Cancer, 2002). The patient’s present
status (alive or dead, and the cause of death) was confirmed from
the death statistics of the statistics of Finland. Completely resected
carcinoma specimens were routinely fixed in 10% formalin,
paraffin-embedded and stained with hematoxylin–eosin (HE)
for histopathological diagnoses. The study was approved by
the Ethical Committee of the Faculty of Medicine, University
of Oulu.
Animals
MMP-8 knockout mice were generated by gene targeting as
previously described (Balbin et al, 2003). Wild-type mice (C57BL/6)
with a similar genetic background were used as controls. All
experiments were approved by and performed according to the
recommendations of the Animal Care and Use Committee at the
University of Oulu.
Induction of tongue SCC in MMP-8 KO mice
Forty-seven 13–16-week-old mice were exposed to tongue SCC-
inducing 4-Nitroquinoline-N-oxide (4NQO, Sigma, USA) (Steidler
and Reade, 1984; Gannot et al, 2004) dissolved in propylene glycol
to a final concentration of 10mgml
 1. The mice were lightly
anaesthetised by Isofluran (Forene
s, Abbott Scandinavia, Sweden)
inhalation and 4NQO was smeared to the left dorsal half of the
tongue 3 times per week for 12 weeks. The mice were killed at 55
weeks by cervical dislocation after inhalation of CO2. The tongues
were dissected and fixed routinely in 10% formalin for paraffin
embedding. Tissue sections were stained with hematoxylin–eosin.
Lesions differentiation was analysed and graded into three classes,
(1); normal epithelium without any carcinogenic changes (no
change), (2); various (mild, moderate, severe) epithelial dysplasias
(dysplasia, including four dysplastic papillomas), and (3); SCC
(cancer). Histological diagnoses were done for a total of 47 tongues
by an expert pathologist.
Cell culture
Human oral SCC C1-cells (Ylipalosaari et al, 2005) were grown in
keratinocyte growth medium including a medium (Gibco BRL, Life
Technologies Inc., Grand Island, NY, USA) containing 10% fetal
bovine serum (EuroClone, Milano, Italy) and supplemented with
antibiotics, 1.8 10
 4M adenine, 5mgml
 1 insulin, 1 10
 10M
cholera toxin, 0.5mgml
 1 hydrocortisone, 10ngml
 1 epidermal
growth factor (all from Sigma Chemical Co., St Louis, MO, USA)
and 7.5% sodium bicarbonate. HSC-3 tongue carcinoma cells were
grown as previously described (Moilanen et al, 2003). HSC-3 cells
were maintained in serum-free medium supplemented with 0.5%
lactalbumin overnight prior to addition of 10nM oestrogen (1, 3, 5
(10)-estradien-3 17 b-diol Steraloids Inc.) overnight. Conditioned
media was collected and the cells were rinsed three times with PBS.
The cells were incubated on ice for 10min with 2% Triton X-100
in PBS for sampling of cell membrane extract. Total proteins
were extracted with Trizol
s (Gibco BRL, Life Technologies Inc.,
Roskilde, Denmark).
RT–PCR
Total RNA was isolated from HSC-3 cells incubated with or
without 10nM oestrogen (1, 3, 5 (10)-estradien-3 17 b-diol
Steraloids Inc.) using Trizol
s (Gibco BRL). RT–PCR was
performed as previously described (Moilanen et al, 2002) using
random decamers (Ambion Europe Ltd., Cambridgeshire, UK).
PCR was performed as previously described using MMP-8 primers
producing a band of 352bp (Moilanen et al, 2002) and b-actin
primers purchased from Ambion Europe Ltd. PCR products were
analysed by standard agarose gel electrophoresis.
Antibodies
The following polyclonal antibodies were used in the immuno-
histochemical stainings: laminin-5 g2-chain (1:1000) (Pyke et al,
1995), MMP-8 (1:200) (Hanemaaijer et al, 1997), MMP-9 (1:1000,
Neomarkers, Fremont, CA, USA), MMP-20 (1:1000) (Va ¨a ¨na ¨nen
et al, 2001), MMP-28 (1:500) (Lohi et al, 2001) and factor VIII
(1:800, Dako A/S, Glostrup, Denmark). MMP-2 (1:2000, Suomen
Bioanalytiikka, SBA, Turku, Finland), MMP-7 (1:80, Calbiochem,
La Jolla, CA, USA), integrin avb6 (6.2G2 at 0.5mgml
 1 (Weinreb
et al, 2004), Biogen Idel, Inc., Cambridge, MA, USA), COX-2
(1mgml
 1, Cayman Chemical, Ann Arbor, Michigan, USA) and
CD31 (1:30, DakoCytomation, Glostrup, Denmark) antibodies
were monoclonal. ER-a (1:100, MC-20, Santa Cruz Biotechnology
Inc., CA, USA) and ER-b (1:500, Ab-24, Lab Vision, CA, USA)
antibodies were polyclonal.
Immunohistochemical staining
Immunohistochemical staining was done as previously described
(Ylipalosaari et al, 2005). Briefly, paraffin sections were depar-
affinised and pretreated. Sections were incubated with the primary
antibody overnight at 41C. Sections incubated with non-immune
rabbit (polyclonal) or non-immune mouse (monoclonal) IgGs
instead of primary antibodies were used as negative controls. The
sections were incubated with biotinylated secondary antibodies
and thereafter with Vectastain Elite ABC reagent (Vector
Laboratories, Burlingame, CA, USA). Finally tissue sections were
stained with diaminobenzidine (Sigma-Aldrich, St Louis, MO,
USA) or 3-amino-9-ethylcarbazole (Zymed, San Francisco, CA,
USA) for 10min. The sections were counterstained with Mayer’s
haematoxylin (Histolab Products AB, Go ¨teborg, Sweden). C1
carcinoma cells were doublestained with actin and MMP-8 using
a method described previously (Ylipalosaari et al, 2005). Bound
MMP-8 antibody was visualised with Alexa 488-conjugated anti-
rabbit secondary antibody (1:200 dilution, Invitrogen Ltd.,
Paisley, UK) and actin was visualised with TRITC-conjugated
phalloidin (5ngml
 1, Sigma).
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Human recombinant MMP-8 (Chemicon International Inc.,
Temecula, CA, USA) was tested for the ability to digest human
recombinant oestrogen receptor-a (ER-a) and oestrogen
receptor-b (ER-b) (Invitrogen, CA, USA). In all 3.1mg of human
recombinant ER-a and 4.1mg of human recombinant ER-b were
used in the assays. The tested enzyme/substrate (E:S) molar ratios
were 1:11 and 1:27 for ER-b and 1:5, 1:12, and 1:33 for ER-a.
The reactions were performed in an incubation buffer (10mM
HEPES, 0.15M NaCl, 5mM CaCl2 (pH 7.4)) in the presence or
absence of MMP inhibitor GM6001, 10mM (Ryss Laboratories) at
371C for 22h. The reactions were stopped by boiling in
4 electrophoresis sample buffer (250mM Tris-HCL; 8% SDS;
40% glycerol; 0.0098% Bromphenol blue (pH 6.8)) for 4min. The
samples were then subjected to SDS–PAGE and cleavage products
were separated in non-reducing conditions. ER-a and ER-b were
detected by immunoblotting as described.
Western blotting
Serum-free HSC-3 culture medium was concentrated with 10K
centrifugal filter tubes (Millipore Bedford, MA, USA). The samples
were subjected to 10% SDS–PAGE gel electrophoresis and
thereafter the proteins were transferred to Immobilon P membrane
(Millipore). The membrane was blocked with 5% non-fat milk for
1h and incubated with MMP-8 antibody (Santa Cruz Biotechnology
Inc., CA, USA) at RT overnight. The membrane was washed and
incubated with anti-goat secondary antibody (1:1000, DAKO A/S,
Glostrup, Denmark) for 1h at RT, washed and incubated with
ABComplex/HRP (1:1000, DAKO A/S) for 1h. The membrane was
treated with ECL western blotting detection reagent for 1min and
then exposed to Hyperfilm-ECL (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
The proteins from the cleavage assays were separated by 12%
SDS–PAGE and electrotransferred onto a nitrocellulose membrane
(Millipore). To identify the digested fragments, the membranes
were incubated overnight with ER-a (MC-20, Santa Cruz
Biotechnology Inc., CA, USA) antibody against the COOH-terminal
part of the receptor at 2mgml
 1 concentration or ER-b (Ab-24, Lab
Vision, CA, USA) antibody against the COOH-terminal part of the
receptor at 2.5mgml
 1 concentration. Biotinylated swine anti-rabbit
immunoglobulin G (IgG) secondary antibody (1:1000 dilution)
(Dako, Glostrup, Denmark) was then allowed to bind for 1h.
Finally the membranes were incubated with avidin/biotinylated
horse radish peroxidise (HRP) complex (Dako) for 1h and the
immunoreactive proteins were visualised with ECL western blotting
detection reagents (Amersham Biosciences, Piscataway, NJ, USA).
Malignancy analysis
Hematoxylin–eosin-stained sections were used for Bryne malig-
nancy score analysis (Bryne et al, 1992) and for measuring the
thickest SCC area. Malignancy score was calculated by determining
five morphological features (degree of keratinisation, nuclear
polymorphism, number of mitoses, pattern of invasion and
lymphoplasmacytic infiltration) from each section and by giving
a score (1–4) to each feature. The separate values were then
summed up into the final malignancy score (5–20). Samples were
Table 1 The disease-specific five-year mortality from 90 tongue SCC
patients
Factors n 5-year mortality (%) 95% CI
Gender
Female 47 22 9–35
Male 43 25 10–40
Age group
26–70 years 59 18 7–29
470 years 31 35 15–55
Clinical stage
a
I and II 51 14 3–25
III and IV 36 32 15–49
Malignancy score (Bryne)
a
Low score 22 5 0–14
High score 65 31 18–44
Thickness of SCC
o6.5mm 33 25 8–42
X6.5mm 57 27 15–39
aThe clinical stage was not reported and the malignancy score not analysed from
three patients.
Table 2 The disease-specific five-year mortality from 80–84 tongue
SCC patients for histological prognostic factors
Factors n
5-year
mortality (%) 95% CI
Microvessel density
Inside carcinoma islands
Slight 26 25 5–45
Moderate or abundant 58 25 13–37
Carcinoma marginals
Slight 29 27 7–47
Moderate or abundant 54 24 12–36
‘Normal looking’ mesenchymal tissue
Slight 36 30 14–46
Moderate or abundant 47 20 7–33
Expression of COX-2
Overview ( 100 magnification)
o1% positively stained cells 40 25 10–40
1–50% positively stained cells 44 21 7–35
Detailed view from ‘hot spots’
( 400 magnification)
o1% positively stained cells 25 28 8–48
1–10% positively stained cells 28 14 1–27
410% positively stained cells 31 29 10–48
Expression of laminin-5 g2-chain
Overview ( 100 magnification)
No staining in cancer cells
o40% of the tumour area 63 19 8–30
X40% of the tumour area 20 31 10–52
Cytoplasmic staining in cancer cells
o40% of the tumour area 57 17 6–28
X40% of the tumour area 26 36 13–59
Staining in basement membrane
o40% of the tumour area 23 27 6–48
X40% of the tumour area 60 21 10–32
Detailed view from ‘hot spots’
( 400 magnification)
Negatively stained cells
o50% of all cancer cells 23 17 0–35
X50% of all cancer cells 60 24 12–36
Positively stained cells
o50% of all cancer cells 10 12 0–36
X50% of all cancer cells 73 23 12–34
Expression of avb6-integrin (score 0–7)
0 7 31 0–69
3–5 28 12 0–25
6–7 45 29 14–44
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sdivided into two categories: low (5–10) and high (11–20) Bryne
score. Thickness of the SCC was determined from the sections by
measuring the thickest SCC area with Leica microscope using Leica
IM50 Image Manager program. The sections were divided into two
groups: those under 6.5mm and those 6.5mm or over.
Immunohistochemical evaluations
All histological evaluations were done at least two times by two to
three calibrated investigators without the knowledge of the clinical
information of the patients. For microvascular density assessment
a method described previously (Weidner et al, 1991) was used with
slight modifications. Briefly, the most highly vascularised areas
(‘hot spots’) based on both factor VIII and CD31 stainings were
selected and counted from three different areas: (i) inside
carcinoma islands, (ii) carcinoma marginals and (iii) at the edge
of the slide, ‘normal looking’ mesenchymal tissue. Cases were
divided into three groups: slight, moderate and abundant
microvascular density . The levels of COX-2 expression were
classified first with low magnification and then with high
magnification as follows; grade 0: o1%, grade 2: 1–10%, grade
3: 410–50% and grade 4: 450% of tumour cells. Immunohisto-
chemical staining for the laminin-5 g2-chain was evaluated by
dividing each slide into negative (N; no staining within cancer
cells), positive (P; cytoplasmic staining within cancer cells) and
basement membrane (BM; the tumour nest periphery was partly
or circumferentially stained) areas. Parts of different areas
were categorised as follows: 1: o20%, 2: 20–40%, 3: 40–60%, 4:
60–80% and 5: 80–100% of the analysed tumour areas. In addition
N and P areas separately were analysed with high magnification as
follows: 1: o25%, 2: 25–50%, 3: 50–75%, and 4: 75–100% of all
tumour cells. The levels of avb6-integrin expression were classified
as follows: 0¼no positive staining, 1¼slight positive staining,
2¼medium positive staining and 3¼strong positive staining in
carcinoma cells. The percentage of positively stained cells of the
tumour was categorised as follows: 0: o1%, 1: 1–25%, 2: 26–50%,
3: 51–75% and 4: 76–100%. Finally the score (0–7) was calculated
by summarising the value of intensity and the category of
positively stained cells. Immunostainings for MMPs were evalu-
ated using MMP-2, MMP-7, MMP-8, MMP-9, MMP-20 and
MMP-28 antibodies, respectively. The staining intensity and the
proportion of the positively stained cells were quantified using a
method described previously (Bachmeier et al, 2000). Briefly, a
five-step grading score was used for the proportion of positively
stained carcinoma cells as follows; score 0: o1 cell, score 1: 1 to
o25 cells, score 2: 25 to o50 cells, score 3: 50 to o75 cells and
score 4:475 cells. A four-step grading was used for the staining
intensity of carcinoma cells as follows; score 0: no positive
staining, score 1: weak positive staining, score 2: moderate
staining, score 3: strong staining intensity. With MMP-8 and
MMP-9 antibodies positively stained cancer cells and positively
stained inflammatory cells surrounding the carcinoma islands
were counted separately, whereas with MMP-2 and MMP-7
antibodies only positively stained cancer cells were counted. For
inflammatory cells only the amount of stained cells was counted,
that is, no grading score was used. MMP-20 was excluded from the
analysis due to the small number of stained carcinoma cells. The
score was calculated by multiplying the mean value of positively
stained cells and the mean value of staining intensity. The levels of
ER-b expression were classified as follows: 0¼no positive staining,
1¼slight positive staining, 2¼medium positive staining
and 3¼strong positive staining in carcinoma cells and also in
inflammatory cells.
Statistical analysis
Five-year mortalities from SCC itself (with 95% confidence
intervals, CI) in various subgroups were estimated by the
Kaplan–Meier method. The relative hazards of death from SCC
(and 95% CIs) associated with each marker under study were
estimated by the Cox proportional hazards regression model,
adjusting for the main known prognostic factors (age, sex, and
TNM stage of the tumour). Mutual bivariate associations between
the various markers were evaluated by computing odds ratios (OR
with 95% CIs) for pairs of the dichotomised versions of these
variables. The response variable in the mice experiment had three
ordered categories: no change, dysplasia, and cancer, but it was
dichotomised by pooling dysplasias and cancer into one category.
The differences in proportion of developing dysplasia or cancer
between the MMP-8 knockout mice and the wild-type C57BL/6
mice, were estimated separately for males and females. This
analysis was performed using the function twoby2 in the package
Epi, version 0.7.0 (Carstensen et al, 2007) attached with the R
environment for statistical computing and graphics, version 2.6.0
(R Development Core Team, 2007). All the other statistical
analyses were performed using the SPSS software version 12.0.1.
RESULTS
The overall mortality from the tongue cancer up to 5 years
following the diagnosis of the SCC was 23%. Case fatality was
generally higher among older patients, those with a more advanced
clinical stage, and/or with a higher than average Bryne malignancy
score, but thickness of the tumour did not predict the outcome
Table 3 The disease-specific five-year mortality from 80–84 tongue
cancer for histological prognostic factors
Factors n
5-year
mortality (%) 95% CI
MMP-2 in cancer cells, score
o0.32 54 28 15–41
X0.32 30 15 1–29
MMP-7 in cancer cells, score
o1.84 52 24 11–37
X1.84 21 26 6–46
MMP-8 in cancer cells, score
o0.78 52 31 17–45
X0.78 31 11 0–23
MMP-8 in inflammatory cells
o0.08 42 24 10–38
X0.08 41 24 10–38
MMP-9 in cancer cells, score
o2.62 53 29 15–43
X2.62 30 19 4–34
MMP-9 in inflammatory cells
o10.20 41 32 16–48
X10.20 42 18 5–31
MMP-28 in cancer cells, score
o0.09 58 26 13–39
X0.09 24 19 2–36
ER-b in cancer cells, staining intensity
0–1¼No or slight positive staining 31 19 4–35
2–3¼Medium or strong positive
staining
35 29 12–45
ER-b in inflammatory cells, staining intensity
0–1¼No or slight positive staining 34 25 8–41
2–3¼Medium or strong positive
staining
33 23 8–38
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s(Table 1). There was no evidence for microvascular density or
expression of factors such as COX-2, laminin-5 g2-chain and avb6-
integrin (Table 2) as being associated with the prognosis. By
contrast, it appeared that subjects with positive immunostaining
for MMP-2, -8, -9, or -28 in the cancer cells or MMP-9 or ER-b in
inflammatory cells would have a better prognosis than other
patients (Table 3). However, the statistical evidence in support of
these observed contrasts was weak.
Bivariate associations between the various markers were also
analysed. High Bryne malignancy score value predicted high level
of avb6-integrin (OR 2.9, 95% CI 1.1–8.2), but MMP-9 and COX2
levels in carcinoma cells (OR 0.17, 95% CI 0.03–0.78; and OR 0.19,
95% CI 0.06–0.65, respectively) were negatively associated with
high Bryne category. Likewise, high level of COX-2 predicted
high MMP-9 level in carcinoma cells (OR 2.7, 95% CI 1.0–7.3), but
laminin-5 g2-chain staining within carcinoma cells was inversely
associated with MMP-9 expression (OR 0.22, 95% CI 0.08–0.61).
Further analysis revealed that the only statistically significant
marker for case fatality was MMP-8 (Table 3). Patients with
tumours lacking MMP-8 expression in cancer cells had a relative
SCC mortality rate of 3.70 (95% CI 1.04–12.5) compared to
patients with some MMP-8 positive immunostaining, when
adjusted for age, sex, and stage of tumour (TNM) by the
proportional hazards model. MMP-8 or MMP-9 expression in
inflammatory cells was not associated with survival (Table 3). In
addition, for all evaluated factors only MMP-8 came up with Cox’s
regression model when age, gender and stage were installed as
main variables. Interestingly, positive MMP-8 expression and
improved survival also showed a tendency to be more prominent
in female tongue cancer patients than in male tongue cancer
patients, but this difference was not found to be statistically
significant. The mortality of patients with no positive MMP-8
immunostaining also increased over time during the 5-year period
(Figure 1). The associations of MMP-8 with gender, oestrogen
receptor levels (separately in cancer cells and in inflammatory
cells), tumour thickness, TNM stage, and tumour grading were not
statistically significant.
To test the hypothesis that MMP-8 plays a protective role in
tongue SCC, 23 MMP-8 knockout (KO) and 24 wild-type C57BL/6
mice were subjected to chemical carcinogenesis with 4-Nitroquino-
line-N-oxide (4NQO) for 12 weeks. Half (6/12) of the MMP-8 KO
female mice in contrast to none of the 12 wild-type C57BL/6 female
mice developed tongue cancer during the experiment (Table 4,
Figure 2). Similarly, dysplasias were more frequent in the tongues
of MMP-8 KO female mice (4/12) than in wild-type mice (2/12). In
male mice no difference in carcinoma development was found
between the mouse groups. There was a strong statistical support
to the observation that the MMP-8 KO female mice developed
tongue cancer more often than the wild-type mice. The estimated
proportion of female MMP-8 KO mice developing either dysplasia
or carcinoma was 67 percent points higher than that of the female
wild-type mice (83 vs 17%; 95% CI for the difference in
proportions: þ21 to þ85 percent points). In male mice the same
contrast was observed to be 20 percent points (95% CI  21 to þ55
percent points).
MMP-8 expression was further analysed in cultured oral SCC
cells by confocal immunofluorescence, which localised MMP-8
immunoreactivity mainly to the tongue carcinoma cell membranes
and to subcellular granules. Lack of MMP-8 was found to have
different effect on male and female mice when experimental SCC
was induced. We therefore investigated the effect of oestrogen on
HSC-3 cells. Molecular forms of MMP-8 were identified from
HSC-3 tongue carcinoma cells by using western blotting which
demonstrated a 75kDa species in HSC-3 cell membrane extracts.
Oestrogen treatment induced expression of a 75kDa MMP-8
species in HSC-3 cells as evidenced by western blotting. To verify
this observation we also performed MMP-8 RT–PCR from HSC-3
cells incubated with or without 10nM oestrogen overnight and
found that MMP-8 mRNA was undetectable in resting HSC-3 cells
while oestrogen treatment induced MMP-8 mRNA expression
(Figure 3).
Because oestrogen acts through the oestrogen receptors,
we investigated the expression of ERs in tongue SCCs.
Both oestrogen receptor-a (ER-a) and oestrogen receptor-b
(ER-b) were expressed in human and mouse tongue SCC cells as
detected by immunohistochemical methods (Figure 4). ER-b
expression was found to weakly correlate with a better prognosis
(Table 3).
To test, whether MMP-8 cleaves ER-a or ER-b, and thus could
have effect on their function, we performed an in vitro cleavage
assay using purified recombinant MMP-8 and ERs. MMP-8 was
found to cleave ER-a in vitro dose dependently (Figure 5). Two
cleavage products of full length ER-a (66kDa) were detected, with
the approximate molecular weights of 44 and 26kDa by western
immunoblotting with an ER-a antibody. The intermediate cleavage
product of 44kDa was detected only with the enzyme/substrate
molar ratio 1:5 (Figure 5A). Only minor cleavage of ER-b by
MMP-8 could be detected (Figure 5B, only the result from E:S
ratios 1:11 shown). Approximately 20kDa and 45kDa cleavage
products of monomeric 53kDa ER-b increased, and around
100kDa dimeric and 200kDa higher molecular weight forms of
ER-b slightly diminished after incubating with MMP-8 (Figure 5B).
The broad-spectrum MMP inhibitor GM6001 abolished the ERs
degradation by MMP-8 (not shown).
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Figure 1 MMP-8 expression in carcinoma cells correlates with improved
survival of tongue cancer analysed with the Kaplan–Meier method.
Table 4 Histological incidence of lesions in 4NQO-treated tongue
sections from MMP-8 KO and wild type mice
Response
Sex Strain No change Dysplasia Carcinoma Total
Male C57BL/6 9 2 1 12
MMP-8 KO 6 4 1 11
Female C57BL/6 10 2 0 12
MMP-8 KO 2 4 6 12
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sDISCUSSION
Our investigation was based upon a unique population-based
collection of 90 surgically treated SCC resection samples of the
mobile tongue. Treatment of the patients in Northern Finland is
very effective; the overall mortality from the disease up to 5 years
was only 23% in this study, while it generally varies within about
40–55% in Finland (Dickman et al, 1999). Worldwide, head and
neck cancer is the sixth most common cancer (Hunter et al, 2005).
Low mortality in this case may hide the significance of some
individual prognostic markers, since patients outcome is most
likely affected more by the effective diagnostic and treatment
strategies than by any of the biological variables. The prognosis
was significantly better in younger patients (26–70 years), in
200 m 200 m
200 m 200 m
AB
CD
Figure 2 Histopathological and clinical analyses of 4NQO-treated tongues from MMP-8 KO and C57BL/6 mice. (A) Normal C57BL/6 male mouse
mucosa stained with hematoxylin and eosin. Clinical tongue on the right. (B) MMP-8 KO male with dysplasia. (C) MMP-8 KO females with invasive SCC.
(D) MMP-8 KO females with invasive SCC. Scale bar¼200mm.
MMP-8 352 bp
-actin 294 bp
85 kDa
50 kDa
E2 –
MW 1 2 3 4 5 6 7 8
A
B C
Figure 3 Localisation and molecular forms of MMP-8 in cultured oral carcinoma cells. Localisation of MMP-8 immunoreactivity in oral SCC cell
membranes and in intracellular granules is demonstrated in green and red staining demonstrates actin (A). MMP-8 and b-actin RT–PCR from HSC-3 tongue
carcinoma cells incubated with or without 10nM oestrogen (E2) overnight (B). Molecular sizes of MMP-8 in HSC-3 tongue carcinoma cells analysed by
western blotting (C). Lanes 1 (no E2) and 4 (E2 added) represent concentrated medium where no MMP-8 is detected. Lanes 2 (no E2) and 5 (E2 added)
represent the cell membrane extracts where a 75kDa species can be seen. Lanes 3 (no E2) and 6 (E2 added) are total proteins where a 75kDa species is
visible only after E2 treatment. Lane 7 is odontoblast medium and lane 8 human saliva used as positive controls where a 58kDa form of MMP-8 can be
detected.
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spatients with lower clinical stages of the tumours (TNM I and II)
and in patients with lower (5–10) Bryne’s malignancy score as
has been shown earlier by us (Kantola et al, 2000) and other
investigators (Piffko et al, 1997). Our results were in line with
Teixeira et al (1996), who also did not find a correlation between
the thickness of the cancer in the deepest tumour areas and
outcome of the patients, but in contrast with a study by Charoenrat
et al (2003) where tumour thickness and survival of the tongue
SCC patients correlated significantly. Also in line with previous
tongue SCC studies, we did not observe any association between
micro vessel density either within the borders or outside the
invasive SCC tissue and prognosis of the patients (Leedy et al,
1994; Hogmo et al, 1999). Unlike Pannone et al (2007), we could
not find a correlation between COX-2 expression and survival, but
COX-2 expression was negatively associated with high Bryne’s
category, which is seen as a predictor for poor prognosis (Bryne
et al, 1992). Unlike published earlier (Ono et al, 1999; Katoh et al,
2002; Gasparoni et al, 2007), cytoplasmic or basement membrane
zone staining for the laminin-5 g2-chain in cancer cells did not
correlate with the outcome of the patient in our study. There are
several reports showing increased avb6 integrin expression in
invasive SCCs (Breuss et al, 1995; Jones et al, 1997; Ramos et al,
1997), but these findings could not be replicated here, although our
results, suffering from wide error margins, were not in any conflict
with the previous ones. Over 90% of our tongue cancers samples
did express avb6 integrin but the expression level did not
statistically correlate with the outcome of the patients. However,
high level of avb6 integrin was associated with high Bryne
malignancy score category and may thus be linked to more
aggressive behaviour and poorer prognosis of the cancer.
MMPs are known to be overexpressed in pathological stages
requiring matrix turnover (Overall and Lopez-Otin, 2002). Of the
molecules analysed in this study, the statistical evidence was
insufficient to make judgments on the association between the
expression of MMP-2, -7, -9, and -28 with survival from SCC of the
tongue. In previous studies, MMP-9 expression is associated with
poor prognosis in tongue and also head and neck SCCs (Juarez
et al, 1993; Kawamata et al, 1998; Nyberg et al, 2002) but there is
also publications where such a correlation has not been found
Kim et al, 2006) However, in our bivariate analysis we observed
a positive association between MMP-9 and COX-2 levels in
carcinoma cells, but negative association with MMP-9 presence
and high Bryne category suggesting that MMP-9 in these samples
reflects, but not statistically significantly, better prognosis of the
disease. In addition, our MMP-28 findings were in the line with Lin
et al (2006). We found a slight trend between positive MMP-28
immunostaining and better prognosis of tongue squamous cell
carcinoma. By contrast, parallel analysis with MMP-8 revealed that
production of this protease was significantly associated with good
clinical outcome in tongue cancer patients. Decock et al (2007)
showed that genetic variation in the MMP-8 gene could influence
breast cancer prognosis. They also noticed that MMP-8 inhibited
breast cancer metastasis. These observations are also in the line
with previous studies where MMP-8 expression was associated
with a better prognosis of skin cancer in mice (Balbin et al, 2003)
and a benign behaviour of cultured breast cancer cells (Agarwal
et al, 2003). However, Stadlmann et al (2003) found that MMP-8
expression in ovarian cancer was associated with a poorer
prognosis. This is probably due to the fact that different cancer
types, or species for that matter, cannot always be directly
AB
CD
50 m 50 m
50 m 50 m
Figure 4 Oestrogen receptor-a and -b immunohistochemical staining in tongue squamous cell carcinoma. Nuclear and cytoplasmic ER-a and ER-b
positivity (red staining) were detected both in mouse and human tongue SCC cells. (A) Mouse SCC stained with ER-a antibody (MC-20). (B) Human SCC
stained with ER-a antibody (MC-20) (C) Mouse SCC stained with ER-b antibody (ab-24). (D) Human SCC stained with ER-b antibody (ab-24). Scale
bars¼50mm.
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scompared with each other. This is the first study to show that
MMP-8 expression in human tongue cancer is significantly linked
with prolonged survival. Consistent with this, we also observed
that MMP-8 deficient mice were more susceptible to tongue SCC
than control mice, this contrast appearing to be more pronounced
in females than in male mice. In addition, we found that MMP-8 is
cell-membrane associated in cultured tongue carcinoma cells and
that oestrogen can induce MMP-8 mRNA and protein expression
in HSC-3 tongue carcinoma cells which could partially explain the
differences in cancer susceptibility between the genders. Similarly,
oestrogen-induced MMP-26 expression has been associated with
improved survival in breast cancer (Savinov et al, 2006). MMP-8
expression was previously linked to positive characteristics in
cultured breast cancer cells (Agarwal et al, 2003) and in mouse
cancer studies (Balbin et al, 2003). Unlike the MMP-26 gene
promoter, the MMP-8 gene promoter does not include an
oestrogen receptor element. In contrast, it includes the CCAAT/
enhancer-binding protein (C/EBP) element (Khanna–Gupta et al,
2005). C/EBP has been shown to associate with ER-a and the
complex then acts as a transcription factor and can regulate gene
promoter activity (Chen et al, 2006). This could explain why
oestrogen induces MMP-8 production in HSC-3 cells. Li et al, 2004
found the MMP-26 gene promoter activity to be stimulated by
oestrogen through the ERs. In addition, MMP-26 can cleave ER-b
in vitro and plays an important antitumorigenic role in hormone-
regulated malignancies by regulating the amount of ER-b and thus
regulating the oestrogen signalling pathway (Savinov et al, 2006).
In this study we found, for the first time, that although ER-b, but
not ER-a, are expressed in normal oral mucosa (Va ¨limaa et al,
2004) they were both faintly produced in the tongue SCC islands.
ER-b is expressed by lymphocytes (To ¨rnwall et al, 1999; Ulziibat
et al, 2006), and interestingly we found a weak correlation for the
expression of ER-b in inflammatory cells with prolonged survival.
We also found that MMP-8 can effectively cleave ER-a and some
cleavage of ER-b in vitro was also detected. Additionally, a dimeric
(about 100kDa) and a higher molecular weight (around 200kDa) form
of ER-b monomer (53kDa) diminished after incubating with MMP-8.
According to these data, it is possible that MMP-8 cleaves the ER-b
dimer and complex forms also in vivo. Dimerisation and stability of ER
dimers is crucial for oestrogen receptor activation and function as a
transcription factor (Tamrazi et al, 2002). These data suggest that
MMP-8 protective role could be related to its ability to regulate the
amount of ERs and thus regulating oestrogen-signalling pathway
during tumour development, especially in hormone-regulated malig-
nancies. This finding also at least partly explains the differences
between MMP-8 KO male and female mice cancer susceptibility. Our
study now supports these data also in human patients with mobile
t o n g u eS C C ,t h em o s tc o m m o nt y p eo fo r a lc a n c e r .
In conclusion, based on both human SCC tissue sample analysis
and mice in vivo carcinogenesis experiments, our study is the first
to provide evidence that carcinoma cell membrane bound MMP-8
should be considered as a protective anti-tumour factor in mobile
tongue SCC and its mechanism of action in tumours may be
oestrogen related.
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